DK1567493T3 - Phenyl-substituerede piperidin-forbindelser til anvendelse som PPAR-aktivatorer - Google Patents

Phenyl-substituerede piperidin-forbindelser til anvendelse som PPAR-aktivatorer

Info

Publication number
DK1567493T3
DK1567493T3 DK03811832T DK03811832T DK1567493T3 DK 1567493 T3 DK1567493 T3 DK 1567493T3 DK 03811832 T DK03811832 T DK 03811832T DK 03811832 T DK03811832 T DK 03811832T DK 1567493 T3 DK1567493 T3 DK 1567493T3
Authority
DK
Denmark
Prior art keywords
phenyl
piperidine compounds
substituted piperidine
ppar activators
ppar
Prior art date
Application number
DK03811832T
Other languages
English (en)
Inventor
Scott William Bagley
Thomas Andrew Brandt
Robert Wayne Dugger
William Andrew Hada
Cheryl Myers Hayward
Zhengyu Liu
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1567493T3 publication Critical patent/DK1567493T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03811832T 2002-11-26 2003-11-14 Phenyl-substituerede piperidin-forbindelser til anvendelse som PPAR-aktivatorer DK1567493T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42950602P 2002-11-26 2002-11-26
PCT/IB2003/005235 WO2004048334A1 (en) 2002-11-26 2003-11-14 Phenyl substituted piperidine compounds for use as ppar activators

Publications (1)

Publication Number Publication Date
DK1567493T3 true DK1567493T3 (da) 2009-06-08

Family

ID=32393563

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03811832T DK1567493T3 (da) 2002-11-26 2003-11-14 Phenyl-substituerede piperidin-forbindelser til anvendelse som PPAR-aktivatorer

Country Status (34)

Country Link
US (2) US7199243B2 (da)
EP (1) EP1567493B1 (da)
JP (1) JP4029091B2 (da)
KR (2) KR100875318B1 (da)
CN (1) CN100439337C (da)
AR (1) AR042131A1 (da)
AT (1) ATE425966T1 (da)
AU (1) AU2003276596B8 (da)
BR (1) BR0316521A (da)
CA (1) CA2507465C (da)
CO (1) CO5570701A2 (da)
DE (1) DE60326752D1 (da)
DK (1) DK1567493T3 (da)
EA (1) EA008928B1 (da)
ES (1) ES2321509T3 (da)
GT (1) GT200300258A (da)
HK (1) HK1083502A1 (da)
HR (1) HRP20050437A2 (da)
IS (1) IS7816A (da)
MA (1) MA27532A1 (da)
MX (1) MXPA05005583A (da)
NL (1) NL1024881C2 (da)
NO (1) NO20052921L (da)
NZ (1) NZ539546A (da)
PE (1) PE20040699A1 (da)
PL (1) PL378268A1 (da)
PT (1) PT1567493E (da)
SI (1) SI1567493T1 (da)
TN (1) TNSN05146A1 (da)
TW (1) TW200424172A (da)
UA (1) UA83202C2 (da)
UY (1) UY28097A1 (da)
WO (1) WO2004048334A1 (da)
ZA (1) ZA200503104B (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL378268A1 (pl) * 2002-11-26 2006-03-20 Pfizer Products Inc. Aktywatory PPAR
WO2005115389A2 (en) * 2004-05-25 2005-12-08 Pfizer Products Inc. Specific ppar agonists for treating negative energy balance
MXPA06013674A (es) * 2004-05-25 2007-02-13 Pfizer Prod Inc Nuevo uso.
KR20070050475A (ko) 2004-08-11 2007-05-15 교린 세이야꾸 가부시키 가이샤 신규 환상 아미노 안식향산 유도체
ATE439347T1 (de) * 2004-11-23 2009-08-15 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure- derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia
EP1862464A4 (en) * 2005-03-23 2010-08-25 Kyorin Seiyaku Kk NEW CYCLIC AMINOPHENYL ALKANIC ACID DERIVATIVE
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
CA2621164A1 (en) * 2005-08-26 2007-03-01 Shionogi & Co., Ltd. Derivative having ppar agonistic activity
WO2007120605A2 (en) * 2006-04-11 2007-10-25 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Treatment for nicotine-induced lung disease using peroxisome proliferator-activated receptor gamma agonists
ES2357992T3 (es) * 2006-12-01 2011-05-04 Actelion Pharmaceuticals Ltd. Derivados de 3-heteroaril(amino o amido)-1-(bifenil o feniltiazolil)carbonilpiperidina como inhibidores del receptor de orexina.
WO2009011872A1 (en) * 2007-07-17 2009-01-22 Merck & Co., Inc. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
UA105758C2 (uk) 2007-07-19 2014-06-25 Х. Луннбек А/С 5-членні гетероциклічні аміди та споріднені сполуки
TW201006816A (en) 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
FR2935511B1 (fr) 2008-08-28 2010-12-10 Oberthur Technologies Procede d'echange de donnees entre deux entites electroniques
FR2935510B1 (fr) 2008-08-28 2010-12-10 Oberthur Technologies Procede d'echange de donnees entre deux entites electroniques
UA107938C2 (en) 2009-08-12 2015-03-10 Syngenta Participations Ag Heterocycles with microbicidal properties
US8716482B2 (en) * 2009-09-25 2014-05-06 Merck Sharp & Dohme Corp. Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
TWI513695B (zh) 2009-10-27 2015-12-21 Merck Sharp & Dohme （１，１，１，３，３，３－六氟－２－羥基丙－２－基）苯基衍生物
EP2363825B1 (fr) 2010-03-04 2016-04-27 Inside Secure Procédé pour conduire une transaction au moyen d'un dispositif NFC
EP2680874A2 (en) 2011-03-04 2014-01-08 Pfizer Inc Edn3-like peptides and uses thereof
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
RU2615769C2 (ru) * 2015-07-29 2017-04-11 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Образования "Уфимский Государственный Университет Экономики И Сервиса" Средство для ингибирования фермента альфа-амилазы
WO2021055936A1 (en) * 2019-09-20 2021-03-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small-molecule inhibitors for the β-catenin/b-cell lymphoma 9 protein−protein interaction
WO2024022521A1 (zh) * 2022-07-28 2024-02-01 南通环聚泰生物科技有限公司 靶向BCL9/β-连环蛋白互相作用的小分子化合物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2025518A1 (da) * 1969-06-05 1970-12-10
US4476311A (en) * 1980-03-12 1984-10-09 The Purdue Frederick Company Analgesic 4-carboxy-pyrrolidin-2-one compound
EP0077607A1 (en) * 1981-09-17 1983-04-27 Beecham Group Plc N-substituted 3-aryl piperidines and derivatives thereof
EP0115607A1 (de) * 1983-01-04 1984-08-15 MERCK PATENT GmbH Tetrahydrocarbazolderivate
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
PT100441A (pt) 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
US5274143A (en) * 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
WO1993007141A1 (en) 1991-10-11 1993-04-15 Smithkline Beecham Corporation Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production
WO1993012086A1 (en) * 1991-12-11 1993-06-24 Ss Pharmaceutical Co., Ltd. Arylamide derivative
JPH05255089A (ja) * 1991-12-18 1993-10-05 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
JP3233991B2 (ja) * 1992-06-26 2001-12-04 株式会社ソフィア 遊技機
ES2156120T3 (es) * 1992-12-08 2001-06-16 Ss Pharmaceutical Co Derivados arilamidicos.
WO1996002250A1 (en) 1994-07-20 1996-02-01 Acea Pharmaceuticals Inc. Haloperidol analogs and the use thereof
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
DE19614204A1 (de) * 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JPH09312086A (ja) * 1996-05-22 1997-12-02 Matsushita Electric Ind Co Ltd 光ディスク再生システム、光ディスク再生方法および光ディスク
AU4050797A (en) 1996-08-02 1998-02-25 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
IT1286497B1 (it) * 1996-11-20 1998-07-15 Italfarmaco Sud Spa Difosfine di tipo misto eteroariliche-ariliche come leganti chirali, relativi complessi con metalli di transizione e impiego di detti
JP3373198B2 (ja) * 1997-12-19 2003-02-04 メルク エンド カムパニー インコーポレーテッド アリールチアゾリジンジオン誘導体
ATE273970T1 (de) * 1998-04-16 2004-09-15 Pfizer Prod Inc N-acyl und n-aroyl aralkylamide
US6376494B1 (en) * 1998-06-15 2002-04-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
HN1999000149A (es) 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
GB9822473D0 (en) 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
US6303637B1 (en) * 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
CA2324330A1 (en) * 1999-11-08 2001-05-08 Ssp Co., Ltd. 4-hydroxy-4-phenylpiperidine derivatives and pharmaceuticals containing the same
US20020045613A1 (en) 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
JP2004507457A (ja) 2000-05-11 2004-03-11 協和醗酵工業株式会社 ２−ピペリドン化合物
PL360495A1 (en) 2000-05-22 2004-09-06 Aventis Pharmaceuticals Inc. Arylmethylamine derivatives for use as tryptase inhibitors
AU2001211337A1 (en) 2000-10-06 2002-04-15 Smithkline Beecham Plc Process for the preparation of aryl-piperidine carbinols and intermediates thereof
EP1325912A4 (en) 2000-10-12 2004-05-12 Ssp Co Ltd 2,2-DIPHENYLBUTANAMIDE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS
JP2002173426A (ja) 2000-12-05 2002-06-21 Ss Pharmaceut Co Ltd 血糖低下剤
WO2002064139A1 (en) * 2001-02-15 2002-08-22 Neurosearch A/S Treatment of parkinson's disease by the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity
WO2002064549A1 (en) * 2001-02-15 2002-08-22 Pfizer Products Inc. Ppar agonists
PL378268A1 (pl) * 2002-11-26 2006-03-20 Pfizer Products Inc. Aktywatory PPAR

Also Published As

Publication number Publication date
CA2507465C (en) 2009-04-28
JP4029091B2 (ja) 2008-01-09
IS7816A (is) 2005-04-20
NO20052921L (no) 2005-08-18
KR100760055B1 (ko) 2007-09-18
JP2006509001A (ja) 2006-03-16
NL1024881A1 (nl) 2004-05-27
UY28097A1 (es) 2004-06-30
KR100875318B1 (ko) 2008-12-22
AR042131A1 (es) 2005-06-08
MA27532A1 (fr) 2005-09-01
SI1567493T1 (sl) 2009-06-30
MXPA05005583A (es) 2005-07-27
DE60326752D1 (de) 2009-04-30
US7199243B2 (en) 2007-04-03
US20040157885A1 (en) 2004-08-12
HRP20050437A2 (en) 2005-10-31
US20070191429A1 (en) 2007-08-16
NL1024881C2 (nl) 2009-09-16
EP1567493B1 (en) 2009-03-18
BR0316521A (pt) 2005-10-04
TW200424172A (en) 2004-11-16
EA008928B1 (ru) 2007-08-31
TNSN05146A1 (fr) 2007-05-14
KR20070063051A (ko) 2007-06-18
GT200300258A (es) 2004-11-30
ATE425966T1 (de) 2009-04-15
AU2003276596B8 (en) 2009-03-05
CA2507465A1 (en) 2004-06-10
ES2321509T3 (es) 2009-06-08
KR20050086794A (ko) 2005-08-30
UA83202C2 (ru) 2008-06-25
CN1717389A (zh) 2006-01-04
EP1567493A1 (en) 2005-08-31
CO5570701A2 (es) 2005-10-31
ZA200503104B (en) 2006-12-27
HK1083502A1 (en) 2006-07-07
CN100439337C (zh) 2008-12-03
PE20040699A1 (es) 2004-10-23
WO2004048334A1 (en) 2004-06-10
PT1567493E (pt) 2009-04-09
EA200500629A1 (ru) 2005-12-29
AU2003276596A1 (en) 2004-06-18
NO20052921D0 (no) 2005-06-15
AU2003276596B2 (en) 2009-02-12
NZ539546A (en) 2007-11-30
PL378268A1 (pl) 2006-03-20

Similar Documents

Publication Publication Date Title
NO20052921D0 (no) Fenylsubstituerte piperidinforbindelser for anvendelse som PPAR aktivatorer
IS7471A (is) Ný efnasambönd
IS7879A (is) Ný efnasambönd
NO20044654L (no) Piperidinoylpiperidiner som 5-HTIF-agonister
DK1501826T3 (da) Substituerede indoler som alpha-1-agonister
ATE368042T1 (de) Cephemverbindungen
IS7827A (is) Ný efnasambönd
IS7793A (is) Nýtt efnasamband
IS7794A (is) Nýtt efnasamband
IS7381A (is) Efnasambönd
IS7414A (is) Oxó-azabísýklísk efnasambönd
NO20045659L (no) Forbindelser
DK1556377T3 (da) Cyclopropylthienylcarboxamider som fungicider
NO20044373L (no) Azetidinderivater som CCR-3-reseptorantagonister
DK1499622T3 (da) Meterotricyclyl-6-alkylidenpenemer som beta-lactamaseinhibitorer
DE60322943D1 (de) Indanverbindung enthaltende nematischflüssigkristalline zusammensetzung
NO20044140D0 (no) New Composition
NO20044185L (no) Laminert plate til anvendelse som foring
NO20044043L (no) Dipyridodiazepioner som revers-transkriptase-inhibitorer
ATA8672002A (de) Spindelantriebskupplung
SE0203348D0 (sv) Novel compounds
SE0203751D0 (sv) New Compounds
SE0200523D0 (sv) New compounds
SE0201925D0 (sv) New compounds
SE0202181D0 (sv) New compounds